Mereo BioPharma

Identifying real healthcare potential

Find out more

Deliver valuable new treatments

Find out more

x x

About us

Company overview

Mereo is a new UK-based speciality biopharmaceutical company focussed on the acquisition and rapid development of innovative medicines that have the potential to transform patient quality of life and improve human health. Mereo intends to optimise the commercial value of programmes by entering into partnering deals at key value inflection points or, for selected opportunities, commercialising products itself. Mereo is building a strong pipeline of innovative medicines, particularly focused in rare and specialist disease areas, through the acquisition of validated, mid-stage development programmes from large biopharmaceutical companies. Mereo has access to an extensive network of experts with experience across multiple clinical disciplines and has entered into a strategic development partnership with ICON, a leading global contract research organisation (CRO), for the clinical development of its portfolio.

Mereo’s initial mid-stage portfolio comprises three exceptionally well characterised, novel products for the treatment of diseases with considerable unmet medical need, acquired from Novartis. Each programme has a comprehensive dataset, including proof of concept clinical studies.

Our team

Mereo’s management team is highly experienced in identifying and selecting new product opportunities, managing clinical development pipelines, capital raising and structuring in- and out-licensing transactions. The team is led by Dr Denise Scots-Knight (Pollard-Knight) as Chief Executive Officer, formerly Managing Partner of the healthcare-focused venture capital investor Phase4 Partners and Dr Peter Fellner as Chairman, who has a wide range of experience in biotechnology and pharmaceutical companies.

  Founders   Non-Executive Directors   Executive management team
Dr. Denise Scots-Knight
   
Richard Bungay
 
Charles Sermon
   
Dr. Alastair MacKinnon
   
John Richard
   
Dr. Peter Fellner
 
Dr. Anders Ekblom
 
Dr. Frank Armstrong
 
Peter Bains
 
Kunal Kashyap
 
Paul Blackburn
 

Our strategy

Strategy

Mereo is based in London and was founded in March 2015 to fund and develop novel, innovative specialist focused products from large pharmaceutical or biotechnology companies.

Pharmaceutical companies face increasingly difficult choices in the allocation of internal resources to their drug development programs. With significant P&L constraints and rich pipelines it has become increasingly difficult for many companies to fully fund and advance development all of their drug candidates, especially beyond Phase 2. Mereo has been formed to take advantage of the global pharmaceutical industry’s drive for creative ways to progress their clinical development pipelines.

Business model

Mereo has acquired an initial mid-late stage portfolio of three exceptionally well characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharmaceuticals. Each of these programmes has a comprehensive dataset for both pre-clinical and proof-of-concept clinical studies. Additional product opportunities are under evaluation.

Mereo’s focus is the development of innovative medicines that have the potential to significantly transform the lives of patients suffering from rare and other specialised conditions around the world. To do this, the company depends on the combination of its team’s expertise in selecting and acquiring product opportunities, creating value in the development pipeline and structuring creative transactions. Mereo’s internal expertise is complemented by a unique partnership with a leading global CRO, ICON.

Mereo combines the operational discipline and efficiency of a small company with the financial resources to conduct comprehensive clinical studies. Mereo will rapidly progress each of the products through further value inflection points before partnering or divesting its products. The company also has the option to directly commercialise products, for example in orphan disease indications.

Partnerships

Mereo has been working closely with ICON since inception. Key features of this relationship include:

  • A dedicated global team working in an integrated way with Mereo on an outsourced basis pre-acquisition of products
  • A partnership that enables rapid initiation of comprehensive clinical development plans
  • An ICON team that works with Mereo on due diligence of new product opportunities, feasibility of different clinical study designs, and reimbursement strategies
  • A relationship that is structured to enable Mereo to expand the product portfolio without the addition of significant internal resources

Product pipeline

Program (indication) | Pre-clinical | PI | PII | PIII

BPS-804

Orphan disease product BPS-804 in Brittle Bone Syndrome is a human monoclonal antibody which is being developed to improve bone density (and thereby reduce fractures) in the orphan disease osteogenesis imperfecta (OI), commonly known as brittle bone syndrome.

OI is an orphan genetic disorder that is characterized by fragile bones that break easily. In addition to fractures, people with OI often have muscle weakness, hearing loss, fatigue, joint laxity, curved bones, scoliosis, and short stature. The majority of cases of OI (possibly 85-90 %) are caused by a dominant mutation in a gene coding for type I collagen, a key component of healthy bone. Treatment of OI is supportive, focusing on minimizing fractures and maximizing mobility, but to date, there are no treatments that address the underlying bone weakness.

BGS-649

BGS-649 in hypogonadotrophic hypogonadism is a novel orally active aromatase inhibitor being developed as a first-line therapy for the treatment of obese men with hypogonadotrophic hypogonadism (HH), with the aim of normalising testosterone levels.

HH in men is a clinical syndrome that results from inadequate levels of testosterone. This can be primary, or secondary due to disruption of one of more levels of the hypothalamic-pituitary-testicular axis. After the age of 30, the level of testosterone decreases by about 1-2% per year. In the obese the decrease in testosterone is increased by the high levels of the aromatase enzyme in the fat tissue. These are both considered secondary hypogonadism. Low levels of testosterone have been related to a range of health outcomes including increasing levels of obesity, cardiovascular disease, hypertension, insulin resistance, type 2 diabetes, depression, and osteoporosis.

BCT-197

BCT-197 in acute exacerbations of COPD is an orally active p38 MAP kinase inhibitor being developed as first-line acute therapy alongside existing treatment and supportive care for acute exacerbations of chronic obstructive pulmonary disease (AECOPD).

An AECOPD is characterised by a sudden worsening in the COPD patient’s symptoms of dyspnoea, cough and sputum production. They last for several days and requiring in a step up of medication and often hospitalisation. AECOPDs occur in the natural course of the disease but are commonly triggered by infections and air pollution but one third does not have an identifiable trigger. Both airway and systemic inflammation are characteristic drivers of the disease.

News and events

02 March 2016
Mereo BioPharma announcement

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES.

Mereo BioPharma Group Ltd

Mereo’s BPS-804 granted U.S. Orphan Drug status for Osteogenesis Imperfecta

London, 2 March 2016 – Mereo BioPharma Group Ltd (“Mereo”), a clinical stage, UK-based, biopharmaceutical company focused on rare and specialty diseases, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted BPS-804 orphan drug designation for the treatment of osteogenesis imperfecta (OI), a rare, chronic genetic disorder that results in bones that can break easily. There are currently no FDA-approved therapies for OI.

OI is a rare condition that affects a minimum of approximately 20,000 and possibly as many as 50,000 patients in the United States. Current treatment largely relies on the acute management of fractures as they occur and the use of bisphosphonate drugs, although these agents are not approved by the FDA for use in this indication. BPS-804 is a fully human monoclonal antibody that works by inhibiting sclerostin, which inhibits the activity of bone-forming cells, known as osteoblasts. Mereo believes that by blocking sclerostin, BPS-804 will induce or increase osteoblast function and maturation of these cells, increasing bone formation and reducing bone resorption, thereby reducing fractures in OI patients. BPS-804 could potentially be a first-in-class therapy for use in this condition. Phase 2 proof of concept data in OI patients demonstrated a statistically significant improvement in bone biomarkers and bone mineral density.

Commenting on today’s announcement, Dr Denise Scots-Knight, CEO of Mereo said:
“Osteogenesis imperfecta is a very painful and debilitating disease for which there is currently no approved treatment in the United States. The FDA orphan drug designation grant is an important regulatory milestone and marks a significant step forward in the clinical development of BPS-804. We believe BPS-804 has the potential to become the first therapy to reduce fractures and improve quality of life in osteogenesis imperfecta patients. Initial clinical data generated with BPS-804 has been highly encouraging and we look forward to progressing this product candidate towards registration.”

The FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the United States. Orphan product designation can provide opportunities for grant funding towards clinical trial costs, tax advantages and FDA user fee exemptions. In addition, if a product that has an orphan product designation subsequently receives the first FDA approval for the indication for which it has such designation, the product is entitled to orphan product exclusivity.

Enquiries
For further information, please contact:

Mereo BioPharma Group Ltd
+44 (0)333 023 7300

Denise Scots-Knight, Chief Executive Officer
Richard Bungay, Chief Financial Officer & COO

Public relations adviser to Mereo:

FTI Consulting
+44 (0)20 3727 1000

Ben Atwell
Simon Conway
Brett Pollard

------------------------------------------------

About Mereo
Mereo is based in London and was founded in March 2015 to develop novel, innovative specialist focused products selected and acquired from large pharmaceutical or biotechnology companies. Mereo’s focus is the development of innovative medicines that have the potential to significantly transform the lives of patients suffering from rare and other specialised conditions around the world.

To do this, the Company utilises the combination of its team’s expertise in selecting and acquiring product opportunities, creating value in the development pipeline and structuring creative transactions.

Mereo’s significant internal drug development expertise is complemented by a partnership with ICON, a leading global CRO. Mereo has acquired an initial mid-late stage portfolio of three well-characterised novel products for the treatment of diseases with considerable unmet medical need from Novartis Pharma AG. Each of these programmes has a strong dataset for both preclinical and proof-of-concept clinical studies. Additional product opportunities are under evaluation.

Mereo combines the operational discipline and efficiency of a small company with the financial resources to conduct comprehensive clinical studies. Mereo intends to progress each of the products through further value inflection points before either partnering or divesting its products or directly commercialising itself, for example in orphan disease indications.

About osteogenesis imperfecta (OI)
OI is an orphan genetic disorder that is characterised by fragile bones that break easily. In addition to fractures, people with OI often have muscle weakness, hearing loss, fatigue, joint laxity, curved bones, scoliosis, and short stature.The majority of cases of OI (approximately 90 %) are caused by a dominant mutation in a gene coding for type I collagen, a key component of healthy bone. Treatment of OI is supportive, focusing on minimising fractures and maximising mobility, but to date, there are no treatments that address the underlying bone weakness.

------------------------------------------------

This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America (including its territories and possessions, any State of the United States and the District of Columbia). This announcement is not an offer of orsolicitation to purchase or subscribe for securities in the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

Download PDF

+
02 March 2016
Mereo BioPharma announcement
10 November 2015
Mereo BioPharma strengthens Board and senior management team

London, 9 November 2015 – Mereo BioPharma Group Ltd (“Mereo”), the recently-formed specialty biopharmaceutical company, is pleased to announce that it has strengthened the Board and senior management team with the following five important appointments with immediate effect:

  • Mr Paul Blackburn: Non-executive Board Director and Chairman of the Audit and Risk Committee
  • Dr Anthony Hall: Head of Orphan Diseases
  • Dr Jacqueline Parkin: Head of Respiratory and Endocrinology
  • Dr Fiona Bor: Head of Intellectual Property
  • Dr Ian Hodgson: Head of Clinical Operations

These appointments follow the appointments of Stewart Jones (Head of CMC), Craig Manchip (Head of QA) and Julian Lord (Financial Controller). Mereo was formally launched in July 2015 when it received a commitment of c.$118 million (£76.5 million) from blue chip institutional investors and simultaneously acquired a portfolio of three innovative clinical-stage development programmes from Novartis Pharma AG. Novartis, through the shares issued in consideration for the acquisition of these products, also holds an equity stake in Mereo.

Commenting on today’s announcement, Dr Peter Fellner, Non-Executive Chairman of Mereo, said:
“I am delighted to welcome Paul to the Mereo Board. He brings extensive financial knowledge and experience of risk management, which will be hugely important in helping us create a UK-based biopharmaceutical leader. We look forward to his contribution, as we continue to progress our mission to deliver innovative medicines to transform patient quality of life and improve human health."

Commenting on today’s announcement, Dr Denise Scots-Knight, CEO of Mereo, said:
“These key appointments are another important step in our strategy of creating a successful specialty biopharmaceutical company, focused on acquiring, rapidly developing and commercialising innovative medicines. We are delighted to have attracted such high calibre people to Mereo’s senior management team. Ian, Jacqueline and Anthony bring a breadth of complementary clinical development experience which, along with Fiona’s expertise in intellectual property, will be incredibly valuable as we progress the development of our existing assets and look for opportunities to expand the pipeline through acquisition or in-licensing deals.”

Paul Blackburn has over 30 years’ experience as a senior finance executive. He spent almost forty years at GlaxoSmithKline, formerly SmithKline Beecham, where he was Financial Controller. Paul has been responsible for the successful development and execution of numerous global financial projects and strategies. He recently concluded a three year period on the GSK Audit and Risk Committee. Paul is also on the Board of Syngene International Limited, a custom research and manufacturing organisation listed on the Indian stock market and is a member of Syngene’s Audit and Risk Committee and Stakeholder Relationship Committee.

Dr Anthony Hall joins from BioMarin where he was Group Medical Director in the Neuromuscular disease area, providing leadership and expertise to the global clinical development programmes for the company’s neuromuscular compounds. Prior to this, he was the Medical Director for Medical Affairs at Prosensa Therapeutics until its acquisition by BioMarin. He has held senior clinical development positions at DCPrime, PSR Group, Yamanouchi Europe and Boehringer Ingelheim. In 2012 he co-founded Findacure, a registered charity to support patient groups for rare diseases. Anthony holds a MBBS from the Royal Free Hospital School of Medicine and a joint honours BSc from King’s College London.

Dr Jacqueline Parkin joins from GlaxoSmithKline, where, for the past 13 years, she held a number of senior clinical development roles and obtained extensive clinical and research expertise in immuno-inflammation, metabolic disorders and infectious disease. Prior to joining GSK in 2002, she spent ten years as a Senior Lecturer & Honorary Consultant in Clinical Immunology at St Bartholomew’s Hospital London. Jacqueline holds a PhD in Immunology from the University of London and an FRCP from Royal College of Physicians.

Dr Fiona Bor has 18 years’ experience in pharmaceutical patent law. Before joining Mereo, she was Vice President and Global Head of IP at Mylan Pharmaceuticals. Prior to this, she was Senior Patent Counsel at TEVA Europe and held patent counsel positions at Carpmaels & Ransford and GlaxoSmithKline. Fiona is a dual qualified CPA / EPA and Patent Litigator and also holds a PhD in Molecular Pharmacology from London University.

Dr Ian Hodgson joins from Takeda Oncology Company, where he was Associate Director, Clinical Operations and the EMEA Regional Oncology Lead. Prior to this, he held senior clinical research positions at Shire Pharmaceutical Development, ICON Development Solutions and Sanofi-Aventis. Ian brings 15 years of global clinical development experience in a broad range of therapeutic areas including oncology, haematology, anti-infectives, cardiovascular, CNS, gastroenterology, ophthalmology, renal and respiratory. Ian holds a PhD in Medical Microbiology from the University of Edinburgh and Queen Margaret University Edinburgh.

Enquiries
For further information, please contact:

Mereo BioPharma Group Ltd
Denise Scots-Knight, Chief Executive Officer
Richard Bungay, Chief Financial Officer & COO
Telephone: 0333 023 7300

FTI Consulting (Public relations adviser to Mereo)
Ben Atwell
Simon Conway
Telephone: 0203 727 1000

Download PDF

+
10 November 2015
Mereo BioPharma strengthens Board and senior management team
29 July 2015
Mereo BioPharma announces formal launch of Company

Mereo BioPharma Group Ltd

Mereo BioPharma announces formal launch of Company; raises $118m (c.£76.5m) and acquires innovative mid-stage clinical product portfolio from leading pharmaceutical company

A new UK company focused on acquiring, rapidly developing and commercialising innovative medicines to transform patient quality of life and improve human health

Highly experienced management team; blue chip and deep-pocketed investors

London, 29 July 2015 – Mereo BioPharma Group Ltd (“Mereo”), a recently-formed speciality biopharmaceutical company, announces that it has successfully raised $118m (c. £76.5m), gross, from blue chip institutional investors and simultaneously acquired a portfolio of three innovative clinical-stage development programmes from Novartis Pharmaceuticals. Novartis, through the shares issued in consideration for the acquisition of products, will also hold an equity stake in Mereo.

Mereo is a new UK-based company whose mission is to acquire and rapidly develop innovative medicines that have the potential to transform patient quality of life and improve human health. Mereo intends to optimise the commercial value of programmes by entering into partnering deals at key value inflection points or, for selected opportunities, commercialising products itself. Mereo is building a strong pipeline of innovative medicines, particularly focused in rare and specialist disease areas, through the acquisition of validated, mid-stage development programmes from large biopharmaceutical companies. Mereo has access to an extensive network of experts with experience across multiple clinical disciplines and has entered into a strategic development partnership with ICON, a leading global contract research organisation (CRO), for the clinical development of its portfolio.

Key investment highlights for Mereo are as follows:

An innovative product portfolio from Novartis
Mereo’s initial mid-stage portfolio comprises three exceptionally well characterised, novel products for the treatment of diseases with considerable unmet medical need, acquired from Novartis. Each programme has a comprehensive dataset, including proof of concept clinical studies. Mereo’s pipeline comprises the following programmes:

BPS-804 in the orphan disease Osteogenesis Imperfecta or Brittle Bone Syndrome is a fully human monoclonal antibody which is being developed to improve bone density (and thereby reduce fractures) in osteogenesis imperfecta (OI), commonly known as brittle bone syndrome.

BCT-197 in acute exacerbations of COPD is an orally active p38 MAP kinase inhibitor being developed as first-line acute therapy alongside existing treatment and supportive care for acute exacerbations of chronic obstructive pulmonary disease (AECOPD).

BGS-649 in hypogonadotrophic hypogonadism is a novel orally active aromatase inhibitor being developed as a first-line therapy for the treatment of obese men with hypogonadotrophic hypogonadism (HH), with the aim of normalising testosterone levels.

Strategic development partnership with ICON
Mereo’s strategic partnership with ICON provides a dedicated global team working closely with Mereo from pre-acquisition through to conduct of global clinical studies for its pipeline products. The relationship has been structured to enable Mereo to expand its product portfolio without the addition of significant internal resources.

A strong investor base
Mereo has secured $118m (c. £76.5m), gross, from UK institutional investors Woodford Investment Management and Invesco Perpetual. In addition, Novartis, through the shares issued in consideration for the acquisition of products, will hold an equity stake in Mereo and intends to make a cash investment in Mereo in future financings.

A highly experienced management team
The team is led by Dr Denise Scots-Knight (Pollard-Knight) as Chief Executive Officer, formerly Managing Partner of the healthcare-focused venture capital investor Phase4 Partners and Dr Peter Fellner as Chairman, who has a wide range of experience in biotechnology and pharma companies. Mereo’s management team is highly experienced in identifying and selecting new product opportunities, managing clinical development pipelines, capital raising and structuring in- and out-licensing transactions.

Commenting on today’s announcement, Dr Denise Scots-Knight, CEO of Mereo said:

“We believe that by acquiring quality assets from Novartis and securing substantial financing we have put in place the building blocks to create a successful specialty biopharmaceutical company. Through the experience and connections of the team and Board we are delighted to have been able to work with a visionary global leader in Novartis Pharmaceuticals in building a new model to help optimise the development of pharmaceutical pipelines. We believe the exceptional experience and track record of the Mereo team and Board will enable us to rapidly build a globally competitive business.”

Commenting on today’s announcement, Dr Peter Fellner, Chairman of Mereo said:

“We believe the substantial fundraising underpinning the launch of Mereo is a strong endorsement from the investment community of our vision to create a UK-based biopharmaceutical leader. This reflects both the extensive experience of the management team and Board, as well as the extremely high quality of programmes acquired from Novartis which form the initial portfolio of Mereo.”

WG Partners LLP acted as advisor to Mereo BioPharma in connection with this transaction

Enquiries

For further information, please contact:
Mereo BioPharma Group Ltd

Denise Scots-Knight, Chief Executive Officer
Richard Bungay, Chief Financial Officer

020 3036 0355

FTI Consulting (Public relations adviser to Mereo)
Ben Atwell
Simon Conway

020 3727 1000

Download PDF

+
29 July 2015
Mereo BioPharma announces formal launch of Company
29 July 2015
Novartis partners with Phase 4 Partners and institutional investors to help create Mereo BioPharma

Read the full press release

+
29 July 2015
Novartis partners with Phase 4 Partners and institutional investors to help create Mereo BioPharma

Contact us

Location map
Mereo Biopharma
1 Cavendish Place
London
W1G 0QF
United Kingdom
Tel: +44 (0)333 0237 300
Nearest Tube
Oxford Circus

Urgent medical enquiries

If you are trying to contact us with an urgent medical enquiry about one of clinical trials outside of our normal working hours (8.30am-17.00pm, Monday to Friday), then please phone 001 919 674 5468.

Securities laws and restricted access

Due to applicable legal restrictions, you may not access the following content. We apologise for any inconvenience this may cause.

Important Notice

WARNING: THIS SECTION OF THE WEBSITE CONTAINS ANNOUNCEMENTS, DOCUMENTS AND INFORMATION (TOGETHER THE INFORMATION), ACCESS TO WHICH MAY BE RESTRICTED UNDER THE SECURITIES LAWS OF CERTAIN JURISDICTIONS. IN PARTICULAR THE INFORMATION IS NOT DIRECTED AT, AND IS NOT ACCESSIBLE BY, PERSONS RESIDENT, OR OTHERWISE LOCATED, IN AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, THE REPUBLIC OF SOUTH AFRICA, THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THE INFORMATION IS BEING MADE AVAILABLE BY MEREO BIOPHARMA PLC (THE COMPANY) IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY. THE AVAILABILITY OF THE INFORMATION IS SUBJECT TO THE TERMS AND CONDITIONS SET OUT BELOW.

Please read this notice carefully

– it applies to all persons who view this webpage. This notice may be amended or updated by the Company from time to time and accordingly it should be read carefully in full each time you wish to view the Information. In addition, the content of the site, and its availability to persons resident in certain jurisdictions, may be amended at any time in whole or in part at the sole discretion of the Company.

Basis of access

Please read this notice carefully before clicking I agree or I disagree below. This notice applies to all persons who view the Information. Access to these materials is being made available on this webpage by the Company in good faith and for information purposes only.

Any person seeking access to this webpage represents and warrants to the Company that they are doing so for information purposes only. Any persons seeking access to the Information represents and warrants to the Company that they are doing so for information purposes only. Making the Information available does not constitute a recommendation by the Company or any other party to sell or buy securities in the Company.

Confirmation of representation

Any person seeking access to this webpage certifies that they are not located in the United States, Canada, Australia, Japan, New Zealand or the Republic of South Africa or any other jurisdiction where the release, publication or distribution of these materials would be unlawful. Any person seeking access to this site confirms that they have read and understood this disclaimer and agrees to be bound by its terms.

The information contained on this website does not constitute an offer of securities for sale in the United States. No securities have been, or will be,registered under the US Securities Act of 1933, as amended (the Securities Act) or with any securities regulatory authority of any state or other jurisdiction in the United States. No securities may be offered, sold, resold, taken up, transferred, delivered or distributed, directly or indirectly, within, into or in the United States except pursuant to an applicable exemption from the registration requirements of the Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States.

Acceptance of this notice

To visit the following pages of the site, you must confirm that you have understood the above sentences and agree to comply with the restrictions. 

By accessing the attached document you:
– confirm that you have read, understood and agree to be bound by the terms of the notice set out above;
– warrant and represent that you are not a resident of, or otherwise located in Australia, Canada, Japan, New Zealand, the Republic of South Africa, the United States or any other jurisdiction where accessing the Information would constitute a violation of the relevant laws or regulations of that jurisdiction;
– agree that you will not transmit or otherwise send (directly or indirectly) any Information to any person in Australia, Canada, Japan, New Zealand, the Republic of South Africa, the United States or any other jurisdiction if to do so would breach any applicable law or regulation; and 
– confirm that you are not a person to whom the communication of the information contained on the site is restricted and are not acting for the benefit of any such person.

By clicking on ‘I agree’ below you confirm you are not governed by any of the above jurisdictions.

Securities laws and restricted access



By clicking the “Submit” button below you certify that you are an individual resident in, and are currently in, the country stipulated by the above, that you have read and understood this notice and the notice on the prior webpage and that you are a person who is permitted under applicable law and regulation to receive information of the kind contained in this website. These materials are not directed at or accessible by persons located in the United States of America.